Audit: QRS - Apigenin for Health & Longevity
Audit conducted on 22/09/2026 16:03 using AI4L / Opus 5
Summary
| Items | Count |
|---|---|
| Total | 94 |
| Passed | 88 |
| Failed | 0 |
| N/A | 6 |
| Pass Rate | 100.00% |
- Total = Passed + Failed + N/A
- Pass Rate = Passed / (Passed + Failed) × 100
- N/A items are excluded from the pass rate calculation
1. General Rules
| # | Description | Result | Comments |
|---|---|---|---|
| 1.1 | Every claim, magnitude, label, recommendation, and statement in the QRS is literally supported by content in the source ER. | 🟢 | Every span traced to source: at-a-glance to ER Conclusion (L492-496); protocol cells to ER Therapeutic Protocol (L364, L366, L376); time cells to ER L175, L419, L359; benefits/risks to ER tier headings; gates to ER L313-340; monitoring table to ER L449-457; cadence to ER L447; qualitative items to ER L461-466. |
| 1.2 | Where the ER uses cautious phrasing (“not formally studied”, “None documented in human trials to date”, “theoretical concern”, “data are limited”), the QRS uses the same phrasing. | 🟢 | “No established timeline” and “No human study has measured one” mirror ER L419; “if present” retained for the sedative effect; “Speculative” and “theoretical platelet effect” carried through from ER L457. |
| 1.3 | The QRS never strengthens an ER claim (e.g., “not formally studied” → “not required”) or softens one (e.g., “do not use during pregnancy” → “use with caution during pregnancy”). | 🟢 | Contraindications stay absolute (pregnancy, transplant, Child-Pugh B/C) as in ER L335-340; the sleep claim is not upgraded — the QRS repeats the null insomnia result alongside the sedative timing. |
| 1.4 | The QRS does not relabel an ER fact under a different decision category. A “Benefit-Modifying Factor” from ER section is not surfaced as a “Caution”; a “Risk-Modifying Factor” is not surfaced as a “Side Effect”; etc. | 🟢 | Contraindications come only from the ER “Populations who should avoid Apigenin” list; Key Interactions only from the ER interaction bullets; no Benefit- or Risk-Modifying Factor is surfaced as a gate. |
| 1.5 | PubMed IDs, study citations, expert names, clinical trial identifiers (NCT*), and brand names appear in the QRS only if they appear in the source ER for the same fact. | 🟢 | The QRS carries no PMIDs, no NCT identifiers, no author names and no brand names; the sepsis pilot trial is referenced generically, as the ER does at L364. |
| 1.6 | The QRS does not introduce new attributions. | 🟢 | No attributions of any kind appear on the sheet. |
2. Focus, Tone & Audience
| # | Description | Result | Comments |
|---|---|---|---|
| 2.1 | The QRS follows the tone of the ER, which is determined by the ER’s own language, phrasing, and framing. | 🟢 | Matches the ER’s measured, sceptical register — “plausible, inexpensive, and unproven in either direction” (ER L496) becomes “Cheap, plausible, and unproven in either direction”. |
| 2.2 | The tone of the QRS is simultaneously expert, accessible, objective, and data-driven, but also empowering and encouraging | 🟢 | Presents the evidence gap plainly while giving the reader concrete, actionable protocol, monitoring and qualitative-assessment anchors. |
| 2.3 | The QRS reads as a trusted, knowledgeable guide rather than a prescriptive doctor | 🟢 | Declarative throughout; no imperative instructions. |
| 2.4 | The QRS avoids language that implies medical or clinical advice | 🟢 | Monitoring and cadence are stated as what the ER describes, not as orders. |
| 2.5 | The QRS “presents information” instead of “providing guidance”, “recommending”, or “advising” | 🟢 | No “recommend”, “advise” or “should” in the QRS’s own voice; e.g. “a 12-week reassessment point is where discontinuation is considered”. |
| 2.6 | The QRS never addresses “the reader” directly — it presents evidence, not guidance | 🟢 | No second-person pronouns anywhere in the file. |
| 2.7 | The QRS is written in plain language, avoiding unnecessary medical jargon | 🟢 | Plain phrasing used wherever the ER allows (“cellular fuel molecule”, “worn-out-cell secretome” from the ER heading); remaining technical terms are drug-class names the gate cannot function without. |
| 2.8 | Information is presented in a concise and very compact manner | 🟢 | Every item is a bare fact; ER elaborations, magnitudes and citations are dropped. |
| 2.9 | It DOES NOT address the reader directly | 🟢 | Confirmed — no direct address anywhere. |
| 2.10 | The target audience is health- and longevity-oriented adults who are risk-aware, proactive, and actively seeking to optimize health or apply the intervention under review. | 🟢 | Protocol, biomarker panel and qualitative self-assessment list all assume a proactive self-experimenter. |
| 2.11 | The target audience is willing to employ lifestyle and behavioral changes as well as follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Monthly home blood-pressure and weight checks plus a seven-marker blood panel presuppose that willingness. |
| 2.12 | The document is NOT written for the general population, who are unwilling to employ lifestyle and behavioral changes or follow protocols that may be inconvenient, costly, or require effort. | 🟢 | Content level and the narrow-therapeutic-index interaction detail are well above general-population framing. |
| 2.13 | Framing, takeaways, and risk/benefit weighting throughout the document reflect this audience, including where an intervention’s signal for the average person differs from its signal for this audience. | 🟢 | The sheet foregrounds that the longevity rationale is unmeasured in humans while the sedative rationale drives the actual protocol — the distinction that matters to this audience. |
| 2.14 | The document’s own voice frames usage in longevity terms, not “anti-aging” (e.g., “anti-aging clinics”, “anti-aging community”, “anti-aging medicine”). Proper names that contain “anti-aging” (e.g., “American Academy of Anti-Aging Medicine”) are quoted verbatim. | 🟢 | The string “anti-aging” does not occur; the sheet uses “ageing-related effect” and “falls with age”. |
| 2.15 | The document’s own voice uses formal clinical and scientific terminology, not colloquial or consumer-grade language (e.g., “oral medication” not “pill(s)”; “oral” / “administered orally” not “taken by mouth” / “given by mouth”; “injection” not “shot”; “adverse event” not “bad reaction”). This holds on EVERY surface, including the QRS lede — the stricter plain-language bar (see 2.7) does not license lay phrasing for route of administration. Direct quotes from sources are exempt. | 🟢 | “capsule”, “dose”, “sedation”, “allergic reactions” used; no “pill”, “shot”, “taken by mouth” or “bad reaction”. The lede’s “evening capsule” matches the ER’s own wording at L492. |
3. Template Integrity
| # | Description | Result | Comments |
|---|---|---|---|
| 3.1 | The following labels and headings on the QRS are fixed and not modified: Card and section headings: “Protocol”, “Time to effect”, “Benefits”, “Risk & Side Effects”, “Monitoring”, “Qualitative Assessment”; Gate headings: “Contraindications”, “Key Interactions”; Tier labels: “High”, “Medium”, “Low”, “Speculative”; Table column headers in Monitoring: “Marker”, “Target”, “Why” | 🟢 | All fourteen fixed strings verified verbatim against the template (QRS L446, L492, L543, L575, L594, L630, L657, L661-663, L781, and the four tier labels). |
| 3.2 | All “<span data-qrs-var=”NAME”>…</span>” from the [qrs_template] are present in the the QRS. | 🟢 | Set comparison of all data-qrs-var names shows zero template variables missing; the only additions are the expected expansions of marker_#* into marker_1..7 and qualitative_item# into 1..6. |
| 3.3 | Spans that are not addressed in a checklist item are left unchanged | 🟢 | The three website=”…” spans (evidence_review, audit, full_review), the disclaimer and the entire <style> block are byte-identical to the template. |
4. Formatting
| # | Description | Result | Comments |
|---|---|---|---|
| 4.1 | When the source ER section is empty, the QRS uses the ER’s own empty-state phrasing verbatim. Typical phrasings are “None documented in human trials to date” and “Not formally studied” | N/A | No source ER section is empty. The three unpopulated tiers (benefits High, risks High and Medium) carry explanatory ER text and are governed by 12.5/13.5, which explicitly forbid empty-state phrasing. |
| 4.2 | Where the ER presents a bulleted item as “Label: content”, the QRS uses the ER’s bold label verbatim as the cell or row label. | 🟢 | Protocol labels “Standard dose”, “Timing” and “Single versus split dosing” are the ER’s bold labels verbatim (ER L364, L366, L376); the interaction gate carries the ER’s bold labels including their example-drug parentheses. |
| 4.3 | Labels are not paraphrased, abbreviated, or invented. | 🟢 | No invented label appears; monitoring row labels are the ER biomarker names verbatim. |
| 4.4 | The QRS DOES NOT use emoji indicators (no 🟩, 🟥, 🟨, etc.). Color and emphasis are conveyed through CSS and bold labels. | 🟢 | Codepoint scan returns no emoji; the ER’s 🟩/🟥/🟨 tier markers and the ⚠️ Conflicted flags were correctly dropped. |
| 4.5 | The QRS is designed to render on one A4 page. Any section that has more content in the ER than fits the per-section budget is condensed by the LLM, not extended onto a second page. | 🟢 | Every section is condensed to bare facts: benefit and risk tiers collapsed into single semicolon-separated lines, gate items stripped of their rationale clauses, monitoring “Why” cells reduced to the ER’s short reason, and the cadence paragraph compressed from ER L447. |
5. Metadata
| # | Description | Result | Comments |
|---|---|---|---|
| 5.1 | The metadata is placed inside a single HTML comment that is the first element after “<!doctype html>” and before any other comment, head, or body content. | 🟢 | QRS L2-14: the metadata comment immediately follows the doctype and precedes the template comment at L16. |
| 5.2 | Inside that HTML comment the YAML block is delimited by a line “—” opening and a line “—” closing. Text before the opening “—” is permitted but is not parsed as YAML. | 🟢 | Opening “—” at L3, closing “—” at L13; the preamble text sits on L2. |
| 5.3 | The metadata is not visible in any rendered view of the QRS and is not surfaced by any other element on the sheet. | 🟢 | Enclosed entirely in an HTML comment; no metadata value is repeated in the head or body. |
| 5.4 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Only duration: "00:03" is quoted, and it contains a colon; all other values are bare and trimmed. |
| 5.5 | The filename of the source ER is stated as “er_filename: [er_filename]” | 🟢 | L4: er_filename: apigenin_2026-0906-0456_Opus_ER.md, matching the ER’s own filename field at ER L17. |
| 5.6 | Version of the QRS.md file used to create the document is stated as “qrs_prompt_version: [Version of QRS.md]” | 🟢 | L5: qrs_prompt_version: 26.9.22, matching the QRS.md version badge. |
| 5.7 | Creation date and time of the document is stated as “qrs_creation_date: [YYYY-MMDD-HHMM]” (e.g., 2026-0501-1430) | 🟢 | L6: qrs_creation_date: 2026-0922-1556 — correct format. |
| 5.8 | The nickname of the AI used to create the document is stated as “qrs_creator_ai_nickname: [qrs_creator_ai_nickname]” | 🟢 | L7: qrs_creator_ai_nickname: Opus. |
| 5.9 | The nickname of the AI is just a single word model name without version, etc. (e.g., Opus, Sonnet, Grok, Gemini, ChatGPT) | 🟢 | “Opus” — single word, no version. |
| 5.10 | The full name of the AI used to create the document is stated as “qrs_creator_ai_fullname: [qrs_creator_ai_fullname]” | 🟢 | L8: qrs_creator_ai_fullname: Opus 5. |
| 5.11 | The full name of the AI consists of the [qrs_creator_ai_nickname] and the model version number and no additional qualifier (e.g., Opus 4.6, Sonnet 3.2, Grok 4.5, Gemini 3.1, ChatGPT 5.4) | 🟢 | “Opus 5” — nickname plus version, no qualifier. |
| 5.12 | The filename of the document is stated as “qrs_filename: [filename of this document]” | 🟢 | L9: qrs_filename: apigenin_2026-0906-0456_Opus_QRS.html, matching the file on disk. |
| 5.13 | All frontmatter values are trimmed: no leading or trailing whitespace, no surrounding quotes unless the value contains a colon, bracket, or leading special character that requires YAML quoting. | 🟢 | Re-verified across all nine keys; no stray whitespace or unnecessary quoting. |
6. Page Title & Header
| # | Description | Result | Comments |
|---|---|---|---|
| 6.1 | [page_title] is set to the [canonical_topic] of the ER frontmatter followed by “ - Quick Reference Sheet” (e.g., “Intervention - Quick Reference Sheet”). The [canonical_topic] is HTML-entity-encoded as needed (e.g., & for &) |
🟢 | QRS L22: “Apigenin for Health & Longevity - Quick Reference Sheet” against ER canonical_topic at L8. |
| 6.2 | [header_topic] is set to the [canonical_topic] of the ER frontmatter, with HTML entities encoded as needed (e.g., & for &) |
🟢 | QRS L417: “Apigenin for Health & Longevity”. |
| 6.3 | [header_subline_date] is set to [qrs_creation_date reformatted as MM/DD/YYYY] | 🟢 | QRS L421: “09/22/2026” from qrs_creation_date 2026-0922-1556. |
| 6.4 | [header_subline_model] is set to [qrs_creator_ai_fullname] | 🟢 | QRS L425: “Opus 5”. |
| 6.5 | No additional header content appears: no badge, version stamp, AKA / alternate names line, source-AI attribution, audit date, or QRS variant marker. | 🟢 | Header holds only the title and the standard subline; the ER’s “Also known as” line (ER L30) was correctly not carried over. |
7. At-A-Glance Section
| # | Description | Result | Comments |
|---|---|---|---|
| 7.1 | [at_a_glance] opens by saying what the intervention is — its kind (e.g., dietary supplement, prescription medication, peptide, plant, procedure, practice) — and what it is used for, in plain language, before any verdict on the evidence | 🟢 | Opens “Apigenin is a plant compound from chamomile, parsley and celery, sold as an evening capsule on two promises…” — kind and purpose stated before any evidence verdict. |
| 7.2 | [at_a_glance] is dense, execution-oriented summary of the ER Conclusion section |
🟢 | Condenses ER L492 and L496 into five clauses covering identity, the two claims, the human-evidence gap and the net verdict. |
| 7.3 | [at_a_glance] is no longer than 70 words | 🟢 | 65 words. |
| 7.4 | Every fact in [at_a_glance] is supported by a distinct passage in the ER. | 🟢 | Plant sources and evening capsule (ER L492); the two promises (ER L37, L492); no purified-apigenin human outcome (ER L492); cells/animals/chamomile extract (ER L492); cheap, plausible, unproven (ER L487, L496). |
| 7.5 | It DOES NOT use acronyms or technical classifications that require specialist knowledge, uses plain-language terms instead | 🟢 | No acronyms; NAD⁺ is rendered as “a cellular fuel molecule that falls with age” and GABA as “calms the nervous system”. |
| 7.6 | It DOES NOT cite specific trials (names, years, sample sizes, p-values) | 🟢 | No trial name, year, sample size or p-value appears. |
| 7.7 | It DOES NOT cite effect sizes, relative risks, or statistical results | 🟢 | No numeric result of any kind. |
8. Contraindications
| # | Description | Result | Comments |
|---|---|---|---|
| 8.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All six items come from the “Populations who should avoid Apigenin” list at ER L333-340. |
| 8.2 | [stop_items] represent the Contraindications from the ER | 🟢 | Six ER populations, six QRS items, one-to-one and in ER order. |
| 8.3 | Individual [stop_items] are formatted as <li></li> | 🟢 | QRS L578-589: six discrete <li> elements inside the stop_items span. |
| 8.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | The ER’s trailing rationales are all stripped: “— safety data are absent…”, “where a shift in drug exposure risks rejection or toxicity”, “in whom conjugation capacity is materially reduced”, “following the standard supplement washout…”. |
| 8.5 | Parenthetical qualifiers from the ER bullet — time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | “Child-Pugh Class B or C” and “within two weeks of scheduled surgery” preserved, as is the chamomile-derived-product condition; only the pure glosses (“a severity grading for chronic liver disease”, “oestrogen- or testosterone-blocking drugs”) are dropped. |
| 8.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | 🟢 | The ER uses no ranking notation in this list; nothing to normalize and no bare symbol carried through. |
| 8.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no population, condition, or scenario for which the intervention should be avoided, deferred, or used only under specialist supervision. |
🟢 | The ER names six such populations, and the section is correspondingly populated rather than empty. |
| 8.8 | If the section is left empty, an HTML comment inside the [stop_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. <!– empty: ER names no population that should avoid the intervention –> | N/A | The section is not empty — six contraindications are listed. |
9. Key Interactions
| # | Description | Result | Comments |
|---|---|---|---|
| 9.1 | The section is derived from the ER Key Interactions & Contraindications section |
🟢 | All ten items come from the interaction bullets at ER L313-331. |
| 9.2 | [caution_items] represent the Key Interactions from the ER, excluding any that are already listed as Contraindications | 🟢 | Ten ER interaction bullets, ten QRS items, in ER order; no contraindicated population is duplicated here. |
| 9.3 | Individual [caution_items] are formatted as <li></li> | 🟢 | QRS L597-620: ten discrete <li> elements inside the caution_items span. |
| 9.4 | Items are as concise as possible. No trailing explanations, no elaborations, no mechanistic rationale, no attributions, no citations, no study details. No content after an em-dash, en-dash, or hyphen-dash (e.g., “— dose reduction required”, “— reduced efficacy”) — these trailing clauses are stripped. Just the key fact. | 🟢 | Every ER severity word and mitigation sentence (“Caution. Additive sedation…”, “Monitor. Quercetin also inhibits CD38…”) is stripped; only the agent class remains. |
| 9.5 | Parenthetical qualifiers from the ER bullet — example drug lists, time windows, severity classes, threshold values, clinical staging — ARE preserved as part of the item, kept as concise as possible (shortened or trimmed where needed to fit the one-page budget, but never dropped entirely). | 🟢 | All six ER example-drug lists are preserved intact; only the explanatory gloss “(a pump that expels drugs from cells)” at ER L317 is dropped, and the ER L331 parenthetical is carried as the item itself. |
| 9.6 | When the ER uses ranking notation inside parens (e.g., “>” for severity ordering) that depends on an explanatory phrase to interpret, normalize the items to a plain comma-separated list rather than carrying through the bare symbol. | 🟢 | The ER uses plain comma-separated drug lists with no ranking symbols; the QRS carries them as comma-separated lists. |
| 9.7 | The section is left empty ONLY IF the ER’s Key Interactions & Contraindications section identifies no interaction, additive effect, or exposure that changes how the intervention is used. |
🟢 | The ER names ten interactions, and the section is correspondingly populated rather than empty. |
| 9.8 | If the section is left empty, an HTML comment inside the [caution_items] span records the ER basis for the absence, naming or quoting the ER text relied on. E.g. <!– empty: ER names no interaction that changes how the intervention is used –> | N/A | The section is not empty — ten key interactions are listed. |
10. Protocol
| # | Description | Result | Comments |
|---|---|---|---|
| 10.1 | The section is derived from the ER Protocol section |
🟢 | All three cells come from the ER “Therapeutic Protocol” section at L362-386. |
| 10.2 | The three sets of [action] items cover the three most important actionable implementation aspects from the ER Protocol section |
🟢 | Dose, timing and single-versus-split dosing are the three executable decisions; the remaining ER bullets are competing positions, attributions, pharmacokinetics or “no guidance exists” statements. |
| 10.3 | If less that three distinct actionable implementation aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | The ER mentions more than three actionable aspects, so all three sets are used and none is left unfilled. |
| 10.4 | All used [action_#label], [action#value], [action#_sub] items are filled with meaningful content derived from the ER Protocol section. |
🟢 | “Standard dose / 50 mg once daily” (ER L364), “Timing / 30–60 min before bed” (ER L366), “Single versus split dosing / Single evening dose” (ER L376); each sub condenses the matching ER sentence. |
11. Time to Effect
| # | Description | Result | Comments |
|---|---|---|---|
| 11.1 | The three sets of [time] items cover the three most important time-to-effect aspects from the ER | 🟢 | Anxiety onset (ER L175), the sedative effect (ER L419) and the absent metabolic/ageing timeline (ER L419) are the only time-anchored effects the ER reports. |
| 11.2 | The sets are picked and ordered by the magnitude of the related benefit | 🟢 | Anxiety is the ER’s strongest human signal (Low tier, ER L171-175), the sedative effect has a null randomised sleep result, and the metabolic effect is Speculative — the ordering follows that ranking. |
| 11.3 | If less that three distinct time-to-effect aspects are mentioned in the ER the unused sets are left empty and made invisible, not filled with placeholder text or empty-state phrasing. | N/A | Three distinct time-to-effect aspects exist in the ER, so all three sets are used. |
| 11.4 | All used [time_#label], [time#value], [time#_sub] items are filled with meaningful content derived from the ER. | 🟢 | “Anxiety / 8 weeks”, “Sedative effect / First night”, “Metabolic or ageing-related effect / No established timeline”; the subs draw on ER L173-175, L419 and L359. |
| 11.5 | If the ER does not provide any information on time to effect, the section is removed completely from the Protocol Panel |
N/A | The ER does provide time-to-effect information (ER L419 “Time to effect”), so the section is correctly retained. |
12. Benefits
| # | Description | Result | Comments |
|---|---|---|---|
| 12.1 | The section is derived from the ER Expected Benefits section |
🟢 | All tier content maps to the ER headings at L163-221. |
| 12.2 | Key variables are [benefits_high], [benefits_medium], [benefits_low], [benefits_speculative] | 🟢 | All four spans present at QRS L545, L548, L554, L562. |
| 12.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Each entry is the ER heading alone; every “Magnitude:” paragraph, P value, sample size and citation is dropped. |
| 12.4 | Parenthetical content — including effect sizes, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | “(new growths in the bowel)” is stripped from the colorectal item, as are the ⚠️ Conflicted flags on the anxiety and testosterone headings. |
| 12.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective <SPAN> is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | 🟢 | ER L159 records no High-tier benefit; QRS L545 sets benefits_high to style="display: none" with no empty-state text. |
13. Risks
| # | Description | Result | Comments |
|---|---|---|---|
| 13.1 | The section is derived from the ER Potential Risks & Side Effects section |
🟢 | All tier content maps to the ER headings at L255-289. |
| 13.2 | Key variables are [risks_high], [risks_medium], [risks_low], [risks_speculative] | 🟢 | All four spans present at QRS L632, L635, L638, L645. |
| 13.3 | Items are as concise as possible. No explanations, no elaborations, no effect sizes, no qualifiers, no attributions, no citations, no study details, no mechanistic explanations, etc. Just the key fact. | 🟢 | Each entry is the ER heading alone; the “Magnitude:” paragraphs and all PMIDs are dropped. |
| 13.4 | Parenthetical content — including frequencies, severity grades, sample notes, mechanistic hints, and example studies — is stripped, NOT preserved. | 🟢 | “(a whole-body allergic reaction)” and the ⚠️ Conflicted flag on the sex-hormone heading are stripped. |
| 13.5 | If no items of a specific sub-section (high, medium, low, speculative) are present the respective <SPAN> is set to “display=none”, not filled with “None documented in human trials to date” or similar empty-state phrasing. | 🟢 | ER L247 and L251 record no High- or Medium-tier risk; QRS L632 and L635 set both spans to style="display: none". |
14. Monitoring
| # | Description | Result | Comments |
|---|---|---|---|
| 14.1 | The section is derived from the ER Monitoring section |
🟢 | Table and cadence both come from “Monitoring Protocol & Defining Success” at ER L443-457. |
| 14.2 | All measurable/quantifiable biomarkers from the Monitoring section are listed |
🟢 | All seven ER biomarker rows are present — hs-CRP, fasting insulin, HbA1c, ALT, TSH, total testosterone/oestradiol, and platelet count with INR — with the ER’s optimal ranges carried over verbatim. |
| 14.3 | [monitoring_cadence] is populated with the monitoring cadence/frequency derived from the ER Monitoring section. It is not left with placeholder text or empty. |
🟢 | QRS L771-775 condenses ER L447: monthly home blood pressure and weight, blood panel at 12 weeks then every 6–12 months, and the 2–4 week narrow-therapeutic-index drug-level check. |
15. Qualitative Assessment
| # | Description | Result | Comments |
|---|---|---|---|
| 15.1 | The section is derived from the ER Monitoring section |
🟢 | Drawn from the qualitative-marker list at ER L461-466. |
| 15.2 | All subjective/qualitative biomarkers from the Monitoring section are listed |
🟢 | All six ER qualitative markers are carried verbatim: sleep onset, remembered awakenings, morning alertness, daytime anxiety and rumination, dream intensity, and afternoon energy and cognitive clarity. |
Issues 22/09/2026 16:03
Pass rate 100.00%. No issues found.